Literature DB >> 7584515

Gangliocytomas of the sellar region--a review.

M J Puchner1, D K Lüdecke, W Saeger, M Riedel, S L Asa.   

Abstract

Gangliocytomas are benign, slow growing neuronal tumors and are found for the most part in children and young adults. They are most often localized in either the spinal cord or the cerebral hemispheres. Gangliocytomas in the sellar region are extremely rare and only 43 such tumors (including 4 own cases) have ever been described in the literature. Although these tumors are genuine rarities without any epidemiological importance, they do provide some interesting information on tumorigenesis of pituitary adenomas: 65% of the sellar gangliocytomas are associated with a pituitary adenoma. 74% of patients with these tumors suffered hormonal oversecretion of at least one of the pituitary hormones (mostly growth hormone). With only one exception, the hypothalamic releasing hormone corresponding to the hormonal oversecretion syndrome could be demonstrated in the gangliocytoma immunohistochemically. Ultrastructural studies could demonstrate close cell to cell contacts between adenoma and gangliocytome cells. All these data support the hypothesis that chronic overstimulation by hypothalamic releasing hormones play a role in the development of hormone secreting pituitary adenomas. However, in contrast to sellar gangliocytemas, extrahypothalamic tumors secreting excessive hypothalamic hypophysiotropic hormones have never been associated with a pituitary adenoma. They have only been associated with pituitary cell hyperplasia. Therefore, the hypothesis can be made that hypothalamic releasing hormones only promote but do not initiate tumorigenesis of pituitary adenomas.

Entities:  

Mesh:

Year:  1995        PMID: 7584515     DOI: 10.1055/s-0029-1211342

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  16 in total

Review 1.  Neurology of the pituitary gland.

Authors:  J R Anderson; N Antoun; N Burnet; K Chatterjee; O Edwards; J D Pickard; N Sarkies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

Review 2.  Infrasellar pituitary gangliocytoma causing Cushing's syndrome.

Authors:  Marie-Eve Domingue; Etienne Marbaix; Jean-Luc Do Rego; Vincent Col; Christian Raftopoulos; Thierry Duprez; Hubert Vaudry; Dominique Maiter
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 3.  My approach to pathology of the pituitary gland.

Authors:  N Y Y Al-Brahim; S L Asa
Journal:  J Clin Pathol       Date:  2006-12       Impact factor: 3.411

4.  Acromegaly due to a growth hormone-releasing hormone-secreting intracranial gangliocytoma.

Authors:  M L Isidro; P Iglesias Díaz; X Matías-Guiu; F Cordido
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

5.  Acromegaly associated with gangliocytoma.

Authors:  R K Crowley; Y Al-Derazi; K Lynch; D Rawluk; C J Thompson; M Farrell; A Agha
Journal:  Ir J Med Sci       Date:  2009-09-30       Impact factor: 1.568

6.  Rare sellar region tumors.

Authors:  D J Halbauer; I Mészáros; T Dóczi; Pál Kajtár; László Pajor; K Kovács; Eva Gömöri
Journal:  Pathol Oncol Res       Date:  2003-07-14       Impact factor: 3.201

7.  Ganglioglioma of the neurohypophysis.

Authors:  B W Scheithauer; A I Silva; J E Parisi; K Kovacs; E Horvath
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

8.  GH and PRL-Producing Pituitary Adenoma with Neuron-Like Differentiation.

Authors:  Ikuo Kobayashi; Toru Kameya; Hidehiro Oka; Heiji Naritaka; Nobuyuki Kawano; Kiyotaka Fujii
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

Review 9.  Immunohistochemical Biomarkers in Pituitary Pathology.

Authors:  Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

10.  Combined gangliocytoma and prolactinoma of the pituitary gland.

Authors:  Shuji Mikami; Kaori Kameyama; Satoshi Takahashi; Kazunari Yoshida; Takeshi Kawase; Toshiaki Sano; Makio Mukai
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.